RedX Pharma is a leading bio-technology company based in Liverpool.
They focus on the development of a wide range of early stage, proprietary small molecule therapies to address high, unmet medical needs in cancer, autoimmune and infectious diseases.
How Langtons Helped
Langtons produced a fully integrated financial projections model, with capability to allow regular updating of actual results, allowing re-forecasting on an individual company and group-wide basis.
The AIM listing raised £15m of capital for RedX Pharma, supporting further growth of the business through the continued progression of the Company’s current pipeline of oncology and infectious disease assets.
Although the principal purpose of the financial projections was to support the AIM listing, the financial model we provided gave the business a tool which allows them to easily provide forecast information, including additional group companies or changing staff dynamics, for all management and shareholder purposes.